Phase Forward to Participate in Key Industry Events in March

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate in four industry events this month including DIA’s 22nd Annual EuroMeeting, the DIA/FDA CDER/CBER Computational Science Annual Meeting, the World CRO Summit 2010 and the Association for Clinical Data Management (ACDM) Annual Conference.

At DIA’s EuroMeeting, to be held March 8-10 in Monaco, Vice President for Phase Forward’s Lincoln Safety Group Wayne Kubick will lead a safety talk on “Evaluating Drug Safety and Effectiveness through the Lens of eHealth Data,” Tuesday, March 9, 4:00 - 5:30 p.m. local time. Later in the month, at the DIA/FDA CDER/CBER Computational Science Annual Meeting, March 22-23 in Bethesda, Md., Kubick will participate in the panel discussion titled, “Janus: Moving Forward and Planning for Transition” on Tuesday, March 23, 8:15 - 9:45 a.m. Eastern Standard Time.

At the World CRO Summit, March 11-12 in Shanghai, China, Jon Carrano, Ph.D., Phase Forward Regional Director, Asia Pacific, will lead a session titled, “Deploying Electronic Data Capture in Asia” on Friday, March 12, 11:30 a.m. - 12:10 p.m. local time.

Additionally, at the ACDM Annual Conference, March 21-23 in Northamptonshire, UK, Edward Jones, Phase Forward Services Manager, will review the benefits in data quality and patient safety through the use of tools like Phase Forward’s Lab Normal Ranges Management Tool (LNMT) in the session, “Realizing the Benefits of Integrating Laboratory Normal Range Data with an EDC System” on Tuesday, March 23, 12:05 - 12:30 p.m. local time.

Phase Forward will also exhibit its integrated clinical research suite (ICRS) at the conferences. Members of the media interested in speaking with Phase Forward should contact Maria Sumner at +44 1628 640743 or maria.sumner@phaseforward.com or Juli Greenwood at 781-672-3137 or jgreenwood@chenpr.com.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024